三磷腺苷终止阵发性室上性心动过速安全剂量的探讨

Safe Dosage of Adenosine Tri-phospate in Terminating Paroxysmal Supraventricular Tachycardia

目的探讨三磷腺苷(ATP)终止阵发性室上性心动过速(PSVT)的安全剂量。方法采用个体化给药原则,自肘静脉快速静脉推注ATP,以0.050mg/kg为初始剂量,0.025mg/kg为递增量,直至终止PSVT或因副作用较严重而不能忍受,每次用药至少间隔3min。结果 120例PSVT患者应用ATP治疗后PSVT全部终止,ATP终止PSVT最小有效剂量是0.05mg/kg,最大剂量0.20mg/kg,应用ATP的剂量与PSVT终止率间有正相关关系(rs=0.89,P<0.01),所有患者均无晕厥,阿斯综合征等严重副作用发生。结论采用个体给药原则,与传统应用ATP终止PSVT的方法比较剂量最小、最安全。

Objective To explore the safe dosage of adenosine tri-phospate （ATP） in terminating paroxysmal supraventricular tachycardia （PSVT）.Methods In xxx patients with PSVT,ATP was individually administrered.The initial dose of ATP was o.o5mg/kg,which was increased at a stepwise increment dosage of 0.025mg/kg each time,until PSVT was terminated or the patient could not tolerate the administration.Each dose of ATP was injected at 3-minute intervals.Results The tachycardia in 120 patients was terminated.The minimal dose of ATP terminating PSVT was 0.05mg/kg,while the maximal dose was 0.2mg/kg.No severe adverse events such as Adames-Strokes syndrome were observed.Conclusion Individualized administration of ATP is preferred.Compared with conventional method,it is with minimal dosage and safer.